Citations

Clear

6273 citation(s) found for "To, Andrew".

The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond 3 Hours Versus Within 3 Hours
Hallevi, Hen , Gonzales, Nicole R. , Barreto, Andrew D. , Martin‐Schild, Sheryl , Albright, Karen C. , Noser, Elizabeth A. , Illoh, Kachi, Khaja, Aslam M., Allison, Teresa A. , Shaltoni, Hashem, Grotta, James C. , Escobar, Miguel Antonio , Grotta, James C

Mayo Clinic

Stroke | January 3, 2008 | Volume: 39 | Issue: 2 | Pages: 473-475

10.1161/strokeaha.107.497651 | PMID 18174476 Get It

Background and Purpose— Recombinant-activated factor VII (rFVIIa) is an investigational treatment for intracerebral hemorrhage (ICH). We have evaluated the drug’s treatment effect based on time to treatment. Methods— ICH patients treated up to 4 hours from symptom onset were divided based on time to treatment: ≤3 hours (3H) and 3 to 4 hours (4H). Head CT was done at baseline and 24 hours. Outcome measures included: ICH growth at 24 hours, mortality, favorable outcome and discharge disposition. A cohort of nontreated matched ICH patients was used to asses the clinical efficacy. Results— Forty-six patients were treated with rFVIIa: 24 in the 3H group (range 70 to 180 minutes), 22 in the 4H group (range 181 to 300). One hundred and forty-eight patients formed the control group. Mean baseline ICH volume was 8.8 mL for 3H and 10.1 mL for 4H. Mean 24-hour volume was 9.3 mL for 3H (absolute increase 1.05 mL, relative increase 11.9%) and 11.5 mL for 4H (absolute increase 1.1 mL, relative increase 10.9%); P =0.47 is for the difference in relative increase. Mortality was 12.5% for 3H group, 13.6% for 4H, and 13.1% for the control. In the 3H group, 58.3% were discharged with a poor outcome, compared with 54.5% in 4H and 54.1% in the control. Thrombotic adverse events occurred in 11.1% of patients treated with rFVIIa. Conclusions— In our off-label with rFVIIa, we did not find evidence of a treatment effect based on time to treatment. Other criteria should be sought to identify patients who might benefit clinically from rFVIIa.
Why Parents Seek Medical Evaluations for Their Children With Mild Acute Illnesses
Voigt, Robert G. , Johnson, Shirley K., Hashikawa, Andrew N. , Mellon, Michael W., Campeau, Lynnelle J., Williams, Arthur R., Yawn, Barbara P. , Juhn, Young J.

Mayo Clinic

Clinical Pediatrics | December 5, 2007 | Volume: 47 | Issue: 3 | Pages: 244-251

10.1177/0009922807308254 | PMID 18057151 Get It

The reasons underlying parents' decisions to seek medical evaluations for their mildly ill children are not well understood. This cross-sectional study tracked parents' requests for on-site medical evaluations at a sick child care program. A logistic regression model identified factors associated with parents' decisions to seek medical evaluations for their children based on the data from parent-completed questionnaires. A convenience sample of 196 parents completed all questionnaires; 62 (31.6%) parents sought medical evaluations. Parents were more likely to seek medical evaluations if they were concerned about missing work (odds ratio = 8.6; 95% confidence interval, 3.3-22.0; P = .0001), if they smoked (odds ratio = 3.7; 95% confidence interval, 1.1-12.4; P = .037), or if their spouse's highest educational attainment was some high school (odds ratio = 0.4; 95% confidence interval, 0.1-1.0; P = .044). The data highlight the problems working parents have in accessing health care during usual working hours and the potential value of convenient health care programs.
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/m
Goldstone, Anthony H., Richards, Susan , Tallman, Martin S. , Buck, Georgina , Burnett, Alan K. , Chopra, Raj, Wiernik, Peter H. , Foroni, Letizia, Paietta, Elisabeth , Litzow, Mark R. , Marks, David I. , Durrant, Jill, McMillan, Andrew , Franklin, Ian M., Luger, Selina M. , Ciobanu, Niculae, Rowe, Jacob M. , Lazarus, Hillard M. , Fielding, Adele K. , Franklin, Ian M.

Mayo Clinic

Blood | November 29, 2007 | Volume: 111 | Issue: 4 | Pages: 1827-1833

10.1182/blood-2007-10-116582 | PMID 18048644 Get It

An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy. Patients received 2 phases of induction and, if in remission, were assigned to allogeneic transplantation if they had a compatible sibling donor. Other patients were randomized to chemotherapy for 2.5 years versus an autologous transplantation. A donor versus no-donor analysis showed that Philadelphia chromosome–negative patients with a donor had a 5-year improved overall survival (OS), 53% versus 45% (P = .01), and the relapse rate was significantly lower (P ≤ .001). The survival difference was significant in standard-risk patients, but not in high-risk patients with a high nonrelapse mortality rate in the high-risk donor group. Patients randomized to chemotherapy had a higher 5-year OS (46%) than those randomized to autologous transplantation (37%; P = .03). Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients. However, the transplantation-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk. There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group. This study is registered at http://clinicaltrials.gov as NCT00002514.
Quality Assessment for CT Colonography: Validation of Automated Measurement of Colonic Distention and Residual Fluid
Deshpande, Keshav K., Summers, Ronald M. , Uitert, Robert L. Van, Franaszek, Marek , Dwyer, Andrew J., Choi, J. Richard , Pickhardt, Perry J. , Brown, Línda Morris , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | November 20, 2007 | Volume: 189 | Issue: 6 | Pages: 1457-1463

10.2214/ajr.07.2327 | PMID 18029885 Get It

History of Allergy and Reduced Incidence of Colorectal Cancer, Iowa Women's Health Study
Prizment, Anna E. , Folsom, Aaron R. , Cerhan, James R. , Ross, Julie A. , Anderson, Kristin E. , Flood, Andrew P. , Cerhan, James R , Prizment, Anna E

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 16, 2007 | Volume: 16 | Issue: 11 | Pages: 2357-2362

10.1158/1055-9965.epi-07-0468 | PMID 18006924 Get It

AbstractPrevious epidemiologic studies have reported that a history of allergy is associated with reduced risk of colorectal cancer and other malignancies. We studied the association between allergy history and incident colorectal cancer (n = 410) prospectively in 21,292 Iowa women followed for 8 years. Allergy was defined from four self-reported questions about physician-diagnosed asthma (a), hay fever (b), eczema or allergy of the skin (c), and other allergic conditions (d). A history of any allergy was inversely associated with incident colorectal cancer: after multivariate adjustment, the hazard ratio (HR) was 0.74 [95% confidence interval (95% CI), 0.59-0.94]. Compared with women with no allergy, women reporting only one of the four types of allergy and women reporting two or more types had HRs of 0.75 (95% CI, 0.56-1.01) and 0.58 (95% CI, 0.37-0.90), respectively (P trend = 0.02). The inverse association persisted in analyses restricted to any type of nonasthmatic allergy (HR, 0.73; 95% CI, 0.56-0.95). HRs were similar for rectal and colon cancers as well as for colon subsites: proximal and distal (HRs for any allergy ranged from 0.63 to 0.78 across these end points). Allergy history, which may reflect enhanced immunosurveillance, is associated with a reduced risk of colorectal cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2357–62)
Inherited Arrhythmias
Lehnart, Stephan E. , Ackerman, Michael J. , Benson, D. Woodrow , Clancy, Colleen E. , Donahue, J. Kevin , Grant, Augustus O., Groft, Stephen C. , January, Craig T., Lathrop, David A. , Lederer, W. Jonathan , Makielski, Jonathan C., Mohler, Peter J. , Moss, Arthur J. , Nerbonne, Jeanne M. , Olson, Timothy M. , Przywara, Dennis A., Towbin, Jeffrey A. , Wang, Lan-Hsiang, Marks, Andrew R. , Brugada, Ramón , George, Alfred L. , Olson, Timothy M

Mayo Clinic

Circulation | November 12, 2007 | Volume: 116 | Issue: 20 | Pages: 2325-2345

10.1161/circulationaha.107.711689 | PMID 17998470 Get It

The National Heart, Lung, and Blood Institute and Office of Rare Diseases at the National Institutes of Health organized a workshop (September 14 to 15, 2006, in Bethesda, Md) to advise on new research directions needed for improved identification and treatment of rare inherited arrhythmias. These included the following: (1) Na + channelopathies; (2) arrhythmias due to K + channel mutations; and (3) arrhythmias due to other inherited arrhythmogenic mechanisms. Another major goal was to provide recommendations to support, enable, or facilitate research to improve future diagnosis and management of inherited arrhythmias. Classifications of electric heart diseases have proved to be exceedingly complex and in many respects contradictory. A new contemporary and rigorous classification of arrhythmogenic cardiomyopathies is proposed. This consensus report provides an important framework and overview to this increasingly heterogeneous group of primary cardiac membrane channel diseases. Of particular note, the present classification scheme recognizes the rapid evolution of molecular biology and novel therapeutic approaches in cardiology, as well as the introduction of many recently described diseases, and is unique in that it incorporates ion channelopathies as a primary cardiomyopathy in consensus with a recent American Heart Association Scientific Statement.
Pneumocystis carinii Exhibits a Conserved Meiotic Control Pathway
Burgess, Joshua W., Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

Infection and Immunity | November 6, 2007 | Volume: 76 | Issue: 1 | Pages: 417-425

10.1128/iai.00986-07 | PMID 17984205 Get It

ABSTRACT Pneumocystis carinii is an opportunistic fungus causing severe pneumonia in immune-compromised hosts. Recent evidence suggests that Pneumocystis exists as separate sex types, though definitive evidence is currently lacking. These studies were undertaken to determine whether Pneumocystis maintains functional meiotic control molecules, which are required for sexual life stages in eukaryotes. Using the Pneumocystis carinii Genome Project database, two partial sequences for meiotic control molecules were detected, namely, PC Ran1 , a presumptive meiotic control kinase, and PC Mei2 , a homologue to a primary activator of meiosis in Schizosaccharomyces pombe . Rapid amplification of cDNA ends was employed to obtain the full open reading frames and to further investigate the functions of these proteins. These presumptive meiotic control molecules were most homologous to molecules present in S. pombe (52% identical and 67% homologous for PC Ran1 and 75% identical and 88% homologous for PC Mei2 by BLAST analysis). Heterologous expression of these Pneumocystis meiotic genes in corresponding temperature-sensitive and knockout strains of S. pombe , respectively, further verified the functions of the PCRan1 and PCMei2 proteins. These proteins were further shown to control downstream components of the meiotic pathway in S. pombe . Lastly, in vitro kinase assays were used to determine that PCRan1p phosphorylates PCMei2p. These experiments represent the first characterization of any proteins in P. carinii involved in meiosis and indicate the presence of a conserved meiotic pathway in Pneumocystis . Elucidation of this pathway will be essential in gaining a greater understanding of this important opportunistic fungal pathogen.
Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide
Kavsak, Peter A. , Ko, Dennis T. , Newman, Alice, Lustig, Viliam, MacRae, Andrew R., Jaffe, Allan S. , Richards, C. Sue , Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | October 11, 2007 | Volume: 53 | Issue: 12 | Pages: 2112-2118

10.1373/clinchem.2007.090613 | PMID 17932131 Get It

Abstract Background: Inflammation in acute coronary syndrome (ACS) can identify those at greater long-term risks for heart failure (HF) and death. The present study assessed the performance of interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1) (cytokines involved in the activation and recruitment of leukocytes) in addition to known biomarkers [e.g., N-terminal pro-brain natriuretic peptide (NT-proBNP)] for predicting HF and death in an ACS population. Methods: In a cohort of 216 ACS patients, NT-proBNP (Elecsys®; Roche) and IL-6, IL-8, and MCP-1 (evidence investigator™; Randox) were measured in serial specimens collected early after symptom onset (n = 723). We collected at least 2 specimens from each participant: an early specimen (median 2 h; interquartile range 2–4 h) and a later specimen (9 h; 9–9 h), and used the later specimens’ biomarker concentrations for risk stratification. Results: An increase in both IL-6 and NT-proBNP was observed but not for IL-8 or MCP-1 early after pain onset. Kaplan–Meier analysis demonstrated that individuals with increased NT-proBNP (>183 ng/L) or cytokines (IL-6 > 6.4 ng/L; above upper limit of normal for IL-8 or MCP-1) had a greater probability of death or HF in the following 8 years (P <0.05). In a Cox proportional hazard model adjusted for both CRP and troponin I, increased IL-6, MCP-1, and NT-proBNP remained significant risk factors. Combining all 3 biomarkers resulted in a higher likelihood ratio for death or HF than models restricted to any 2 of these biomarkers. Conclusion: IL-6, MCP-1, and NT-proBNP are independent predictors of long-term risk of death or HF, highlighting the importance of identifying leukocyte activation and recruitment in ACS patients.
Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM
Chahin, Nizar, Engel, Andrew G. , Chahin, Nizar

Mayo Clinic

Neurology | September 19, 2007 | Volume: 70 | Issue: 6 | Pages: 418-424

10.1212/01.wnl.0000277527.69388.fe | PMID 17881720 Get It

Association of Plasma Resistin With Glomerular Filtration Rate and Albuminuria in Hypertensive Adults
Ellington, Allison A., Malik, A. Rauoof , Klee, George G., Turner, Stephen T. , Rule, Andrew D. , Mosley, Thomas H. , Kullo, Iftikhar J.

Mayo Clinic

Hypertension | September 5, 2007 | Volume: 50 | Issue: 4 | Pages: 708-714

10.1161/hypertensionaha.107.095257 | PMID 17785630 Get It

Resistin, a recently discovered proinflammatory cytokine, has been variably associated with insulin resistance, inflammation, and renal dysfunction. We investigated the association of plasma resistin with estimated glomerular filtration rate and albuminuria in 1575 hypertensive adults without known coronary heart disease or stroke (857 blacks and 718 non-Hispanic whites). Resistin was measured by a solid phase sandwich immunoassay, estimated glomerular filtration rate was estimated from serum creatinine, and albuminuria was expressed as urine albumin:creatinine ratio. After adjustment for coronary heart disease risk factors (age, sex, body mass index, smoking history, systolic blood pressure, diabetes, and total and high-density lipoprotein cholesterol) and use of renin-angiotensin blockers and statins, higher plasma resistin levels were associated with lower estimated glomerular filtration rate in both ethnic groups (each P <0.0001); the association remained significant after further adjustment for a marker of insulin resistance (homeostasis model assessment for insulin resistance) and a marker of inflammation (plasma C-reactive protein) and was seen in subjects with and without diabetes (each P <0.0001) in both ethnic groups. Higher plasma resistin levels were associated with a higher urine albumin:creatinine ratio in black subjects with diabetes ( P <0.0001) and non-Hispanic white subjects with diabetes ( P =0.032), independent of coronary heart disease risk factors, hypertension medication use, and statin use; the association remained significant after additional adjustment for homeostasis model assessment for insulin resistance and C-reactive protein. In adults with hypertension, higher circulating resistin levels were associated with a lower estimated glomerular filtration rate and with increased urine albumin:creatinine ratio in the presence of concomitant diabetes. This association was independent of coronary heart disease risk factors and markers of insulin resistance and inflammation.